Is BPC-157 legal or FDA approved? (2026 status)

Quick answer No to both, as of October 2026: BPC-157 is not an FDA-approved drug, and it isn't on the list of ingredients licensed pharmacies may compound, so no pharmacy can legally compound it and no provider can prescribe it through one. In July 2026 an FDA advisory committee recommended adding it to that list, according to news reports, against the advice of FDA's own staff. That recommendation changed nothing by itself: only a rule from FDA can add an ingredient, and FDA hadn't proposed one as of October 2026. If you want to know when that changes, the form at the end of this page is the one way to hear.

Where BPC-157 stands on each FDA list

Most confusion online comes from treating separate FDA lists as one. A substance can be missing from all of them at once, and in October 2026 BPC-157 is.

The three categories are an interim enforcement policy, not law. The bulks list is the rule that counts, and only rulemaking changes it. How the categories work is explained here.

Is BPC-157 FDA approved?

No. FDA's July 2026 briefing document says no approved product contains it in any country, and that it is not a component of an FDA-approved drug.

FDA describes BPC-157, also called Bepecin or PL-14736, as a peptide reported to be made of 15 amino acids, with no United States Pharmacopeia or National Formulary monograph. Sources often don't say whether they mean the free base or the acetate salt, which FDA treats as two different substances.

What changed in 2026, and what didn't

None of these steps made BPC-157 lawful to compound.

September 29, 2023: Category 2. FDA placed it on its safety-concern list, citing a possible risk of immune reactions, peptide-related impurities, difficulty characterizing the ingredient, and little or no safety information.

April 22, 2026: off Category 2. FDA gave notice on April 15 and removed it a week later, along with eleven other substances, because the nominations had been withdrawn by the nominators. FDA's guidance says a withdrawal does not reflect an FDA determination about the validity of the nomination. Coming off a warning list did not make it allowed: it did not move into Category 1, and FDA's safety page still carries its BPC-157 statement.

July 23, 2026: the advisory committee. FDA brought BPC-157 to its Pharmacy Compounding Advisory Committee anyway, evaluated for ulcerative colitis. FDA's own reviewers proposed against adding it to the bulks list. They said it is not well characterized, that there is little information on its safety and its risk of immune reactions, that the evidence on effectiveness for that use was insufficient, and that approved treatments for the disease exist.

FDA has not posted a vote record, minutes or a transcript; its meeting page was last updated August 6, 2026 and showed none when checked on October 6. According to news reports (CNN and AJMC, July 31, 2026), the committee voted to recommend adding BPC-157. FDA has posted no vote record, so this page prints no tally. FDA's meeting page calls such recommendations non-binding.

October 6, 2026: no proposed rule. A Federal Register search that day found no proposed rule on BPC-157; the only document naming it is the April 2026 meeting notice. FDA has announced no timetable.

What it would take for licensed pharmacies to compound it

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy may compound with a bulk ingredient only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the bulks list. The ingredient must also come from an FDA-registered manufacturer with a valid certificate of analysis. BPC-157 meets none of the three routes today, which is why licensed pharmacies can't compound it.

Two things could change that.

• Rulemaking. FDA would publish a proposed rule in the Federal Register, take public comments, then publish a final rule. No proposed rule existed as of October 6, 2026.
• Category 1. FDA could place it in its interim Category 1. That is enforcement discretion, not a change in the law, and FDA has announced no such step.

Any date you see online is a guess. How FDA or a state board would treat a particular pharmacy is a legal question for that pharmacy's counsel.

Is this right for me?

Right now this isn't a choice a provider can make with you. Licensed pharmacies can't compound BPC-157 and there is no FDA-approved product to dispense, so no provider can prescribe it through a licensed pharmacy, whatever your reason for asking.

What you can do today:

• Use the sign-up at the end of this page if you want availability news. Joining reserves nothing.
• Talk to your own doctor about what's prompting the question, and which approved treatments exist for it.
• Avoid "research use only" products. The label is not a legal route to human use, and the risks are set out under Safety information below.

If the rules do change, a licensed provider in your state would still review your health history, medications and goals, and decide. The answer may be no.

How it works

1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
2. Hear from us only if it becomes available through a licensed provider. We write about availability and nothing else, and you can unsubscribe anytime.
3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If FDA's rules change, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is BPC-157 banned? Not in the sense most people mean. It came off FDA's Category 2 safety-concern list on April 22, 2026, after the nominations were withdrawn. It isn't authorized either: it isn't approved, it isn't on the bulks list and it isn't in Category 1.

Did the July 2026 vote make BPC-157 legal? No. News reports say the committee recommended adding it to the bulks list. The committee advises, only a final rule adds a substance, and no proposed rule had been published as of October 6, 2026.

Is BPC-157 a controlled substance? No. It does not appear in the federal controlled-substance schedules (21 CFR Part 1308). Its limits come from drug-approval and compounding law. Separately, FDA's briefing notes that the World Anti-Doping Agency prohibits it in sport.

Can a doctor prescribe BPC-157? A prescription doesn't create a lawful source. Licensed pharmacies can't compound it until it is on the bulks list or FDA changes its policy, and there is no approved product to dispense.

Is "research use only" BPC-157 legal? The label is not a legal route to human use. In August 2026 FDA told five online peptide sellers in writing that a "research use only" label did not change its view when their websites showed the products were meant for people, and none of those letters named BPC-157. What the label means is explained here.

What this means for you

As of October 2026, licensed pharmacies can't legally compound BPC-157 for patients: it isn't on FDA's 503A bulks list, and only FDA rulemaking changes that. If FDA lists it one day, the legal route would be a prescription from a licensed provider in your state, filled by a licensed pharmacy; compounded medications are not FDA-approved. Until then, products sold online as "research use only" aren't made for people.

The July 2026 FDA peptide vote, explained covers all seven peptides the committee reviewed and what has to happen next.

Safety information

BPC-157 is not an FDA-approved drug, and licensed pharmacies can't compound it, so there is no FDA-approved, labeled product to describe here. This is what FDA has said.

• FDA's safety statement, word for word: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."
• What that means: immunogenicity is the risk of an immune reaction. The statement records what FDA doesn't know, not a finding of harm, and it is still on FDA's page.
• Adverse-event reports: FDA's July briefing noted a few reports in its database, such as injection-site reactions, and said it was unclear whether the substance caused them. Reports like these can't show cause either way.
• "Research use only" products: they are not prepared by a licensed pharmacy for a named patient, no prescriber reviews your health history, and nothing assures you of what is in them, how pure it is or whether it is sterile. FDA's reviewers also noted that sources often don't make clear which form of the substance they mean. Everlon never sells "research use only" products.
• Compounded medicines in general: compounded medications are not FDA-approved, which would remain true even if a licensed pharmacy could one day prepare this substance.

If you have used a product sold under this name and something feels wrong, stop and contact a doctor; you can also report the reaction to FDA's MedWatch program. If this is a medical emergency, call 911.

Sources

• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), updated May 14, 2026. fda.gov, accessed 2026-10-06
• FDA. Interim categories list, version updated April 22, 2026 (archived copy). web.archive.org, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (archived copy of April 21, 2026, showing the September 29, 2023 Category 2 date). web.archive.org, accessed 2026-10-06
• FDA. Guidance for industry: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (January 2025). fda.gov, accessed 2026-10-06
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026). fda.gov, accessed 2026-10-06
• FDA. FDA Briefing Document: BPC-157 (free base) and BPC-157 acetate. Pharmacy Compounding Advisory Committee, July 23, 2026. fda.gov, accessed 2026-10-06
• FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register 2026;91:20465. FR Doc. 2026-07361, Docket FDA-2025-N-6895. April 16, 2026. federalregister.gov, accessed 2026-10-06
• Federal Register. Document search: "BPC-157", all agencies, newest first. federalregister.gov, accessed 2026-10-06
• FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
• 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
• 21 CFR Part 1308, Schedules of controlled substances. ecfr.gov, accessed 2026-10-06
• CNN. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. July 31, 2026 (news report). cnn.com, accessed 2026-10-06
• AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report). ajmc.com, accessed 2026-10-06